China
Africa
Explore chapters and articles related to this topic
Papulosquamous Diseases
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Melek Aslan Kayıran, Jordan V. Wang, Ayşe Serap Karadağ
Various biologic agents can target specific molecules and pathways in the psoriasis pathway. They generally have more systemic side effects and risks than other systemic immunosuppressant regimens. Common biologic agents include tumor necrosis factor-alpha inhibitors (e.g., adalimumab, etanercept, certolizumab), IL-17 inhibitors (e.g., secukinimab, ixekizumab, brodalumab), IL-12/23 inhibitors (e.g., ustekinumab) and IL-23 inhibitors (e.g., guselkumab, risankizumab). Biologic treatments are mainly approved for psoriasis vulgaris and psoriatic arthritis and are generally not as effective for pustular psoriasis.
Major Histocompatibility Complex and Autoimmune Disease
Published in Richard K. Burt, Alberto M. Marmont, Stem Cell Therapy for Autoimmune Disease, 2019
Ursula Holzer, Gerald T. Nepom
Psoriasis vulgaris is a chronic inflammatory skin disease. An association of psoriasis vulgaris with HLA antigens was first described in 1972.53,54 Since then, several markers at HLA-loci have been associated with the disease, with HLA-Cw6 demonstrating the strongest correlation.55 Although the combination of HLA-Cw*0602 with HLA-B*5701 shows a high susceptibilty for this disease,5 other studies imply that the susceptibility determinants are not encoded by HLA-A, -B, -C, -DRB1 and -DQB1 and that multiple disease alleles have arisen at the trait locus during the evolution of humans.57
The Integrin α 6β4 in Epithelial and Carcinoma Cells
Published in Yoshikazu Takada, Integrins: The Biological Problems, 2017
Vito Quaranta, Ginetta Collo, Carla Rozzo, Lisa Starr, Guido Gaietta, Richard N. Tamura
Potentially informative is also the behavior of α6β4 in psoriatic keratinocytes.32,33 Psoriasis vulgaris is a relatively common skin disease, characterized by hyperproliferation of keratinocytes. In involved skin from these patients, the expression of α6β4 is altered in two respects: first, it is no longer limited to the basal layer of keratinocytes, but it extends to cells in suprabasal position; second, it is no longer polarized, but it is distributed over the entire surface of cells. Although psoriatic keratinocytes are clearly nonneoplastic cells, their proliferation is not properly controlled. This could, therefore, be considered another example of association between overexpression of α6β4 and uncontrolled proliferative state.
Biological treatment for erythrodermic psoriasis
Published in Expert Opinion on Biological Therapy, 2022
EP is a rare and extreme subtype of psoriasis that tends to be less responsive to conventional therapies. In recent years, biologics have transformed the management of psoriasis vulgaris. Biologics have exceptional short-term and long-term efficacy in patients with psoriasis, with high-quality evidence supporting their use. Literature on EP is much less robust, and the evidence is largely based on retrospective case series and anecdotal case reports. Due to the possibility of publication bias, the results from these reports should be interpreted with caution. TNF-α inhibitors have shown rapid action in patients with EP. Concerns associated with use of these agents include risk of serious infections and secondary therapeutic failure due to development of anti-drug antibodies, particularly with infliximab. Ustekinumab has also shown high efficacy with rapid onset of action in EP patients, including those who had failed prior TNF-α treatment. Convenient dosing schedule and maintenance of treatment response make it an appealing option for long-term management of EP. IL-17 and IL-23 blockers have shown immense therapeutic potential in EP patients with favorable adverse effect profile; however, large-scale studies with longer follow-up period are needed to establish safety and efficacy.
Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics for the treatment of psoriasis
Published in Expert Opinion on Drug Delivery, 2021
Based on clinical manifestations, psoriasis can be categorized into five types, namely, psoriasis vulgaris, inverse, guttate, erythrodermic, and pustular psoriasis. Usually, a patient is affected by only one particular type at a time. The treatment regime depends on the criticality of the disease and varies among patients [5]. Out of all the different types, psoriasis vulgaris occurs in majority of the cases. In this type, reddish round or oval plaques are found in the joint region like knees and elbows [6]. Inverse psoriasis is also known as flexural psoriasis and occurs in folded regions of the body like armpits, genitals, breasts, etc. Nearly 18% of psoriatic patients suffer from this type [7]. Guttate psoriasis generally starts from childhood and occurs due to bacterial infection. Here, tiny droplet-like sores appear on arms, scalp, and legs [8]. Erythrodermic psoriasis is an inflammatory form of this disease that forms scales and redness to most of the body parts. Some patients experience tachycardia, shading of scales and sudden change in body temperature [9]. The last type, pustular psoriasis, is usually seen as pustules on the skin of feet or hands. Very few psoriatic patients are affected by this type [10]. Psoriatic patients also suffer from other morbidities. They have high risks of depression and metabolic complications. Additionally, it has been observed that around 30% of psoriatic patients suffer from psoriatic arthritis [11,12].
Correlation analysis between IL-35, IL-36γ, CCL27 and psoriasis vulgaris
Published in Journal of Dermatological Treatment, 2021
Jiao Chen, Jiaxi Du, Yiyang Han, Zhiping Wei
This case-control study was performed on 30 psoriasis patients who were treated in Xuzhou Medical University Affiliated Hospital from February 2019 to July 2019. Case group inclusion criteria: (i) consistent with the diagnosis of psoriasis vulgaris, and clinical features, laboratory tests, imaging examinations support the diagnosis; (ii) no systematic use of glucocorticoids, vitamin A acid within 2 months before enrollment Drugs, biological agents and immunosuppressive patients; (iii) do not combine autoimmune diseases (such as lupus erythematosus, dermatomyositis), malignant tumors, allergic diseases (such as urticaria, allergic asthma); (iv) sign patient informed consent. Exclusion criteria: (i) pregnant women, lactating women; (ii) systemic infection or systemic diseases; (iii) combined with autoimmune diseases; (iv) glucocorticoids, retinoic acid and immunosuppressive drugs were used systemically within 2 months before the test.